PPA
SPRO icon

Parametric Portfolio Associates’s Spero Therapeutics SPRO Stock Holding History

Parametric Portfolio Associates’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$384K Buy
+44,168
New +$453K ﹤0.01% 3199
2021
Q4 		– Sell
-11,308
Closed -$208K – 3697
2021
Q3 		$208K Sell
11,308
-18,639
-62% -$299K ﹤0.01% 3425
2021
Q2 		$418K Sell
29,947
-1,490
-5% -$20.8K ﹤0.01% 3157
2021
Q1 		$463K Buy
31,437
+5,982
+24% +$105K ﹤0.01% 3533
2020
Q4 		$494K Buy
+25,455
New +$397K ﹤0.01% 3390
2020
Q3 		– Sell
-11,575
Closed -$157K – 3971
2020
Q2 		$157K Buy
+11,575
New +$130K ﹤0.01% 3693
2020
Q1 		– Sell
-10,053
Closed -$97K – 4004
2019
Q4 		$97K Buy
+10,053
New +$108K ﹤0.01% 3866

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Parametric Portfolio Associates's SPRO Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Spero Therapeutics (SPRO) in Q1 2022: 44,168 shares worth $384K. The stake represents ﹤0.01% of the portfolio and ranks #3199 among its holdings. This is a return to the name: Parametric Portfolio Associates previously reported a position in SPRO as recently as Q3 2021.

Parametric Portfolio Associates first reported a position in SPRO in Q4 2019 and has held it in 7 quarters since. The position peaked at $494K in Q4 2020. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • Parametric Portfolio Associates held 44,168 shares of Spero Therapeutics worth $384K as of Q1 2022.
  • Spero Therapeutics was a new Parametric Portfolio Associates position in Q1 2022.
  • Spero Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3199 holding.
  • Parametric Portfolio Associates first reported a position in Spero Therapeutics in Q4 2019 and has held it in 7 quarters since.
  • Parametric Portfolio Associates's Spero Therapeutics position peaked at $494K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.